DASOTRALINE
Total Payments
$5.4M
Transactions
2,150
Doctors
41
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $111,059 | 197 | 24 |
| 2017 | $5.3M | 1,953 | 23 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.2M | 1,670 | 95.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $164,378 | 53 | 3.0% |
| Travel and Lodging | $55,385 | 206 | 1.0% |
| Food and Beverage | $10,236 | 215 | 0.2% |
| Consulting Fee | $4,469 | 6 | 0.1% |
Payments by Type
Research
$5.2M
1,670 transactions
General
$234,467
480 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| DASOTRALINE BINGE EATING DISORDER EXTENSION STUDY | Sunovion Pharmaceuticals Inc. | $1.8M | 1 |
| A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder | Sunovion Pharmaceuticals Inc. | $1.1M | 1 |
| DASOTRALINE ADULT ADHD STUDY | Sunovion Pharmaceuticals Inc. | $791,217 | 1 |
| DASOTRALINE PEDIATRIC ADHD STUDY | Sunovion Pharmaceuticals Inc. | $493,740 | 0 |
| DASOTRALINE BINGE EATING DISORDER STUDY | Sunovion Pharmaceuticals Inc. | $398,319 | 1 |
| A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. | Sunovion Pharmaceuticals Inc. | $196,529 | 0 |
| DASOTRALINE PEDIATRIC EXTENSION STUDY | Sunovion Pharmaceuticals Inc. | $147,357 | 0 |
| Dasotraline Binge Eating Disorder Extension Study | Sunovion Pharmaceuticals Inc. | $118,261 | 0 |
| OPEN-LABEL SAFETY STUDY IN ADULTS WITH ADHD | Sunovion Pharmaceuticals Inc. | $38,008 | 0 |
| Dasotraline Binge Eating Disorder Study | Sunovion Pharmaceuticals Inc. | $20,219 | 0 |
Top Doctors Receiving Payments for DASOTRALINE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $5.1M | 1,644 |
| , MD | Psychiatry | Lincoln, NE | $26,761 | 20 |
| , M.D | Psychiatry | Saint Charles, MO | $22,657 | 41 |
| , MD | General Practice | Rochester, NY | $18,017 | 6 |
| , MD | Psychiatry | Rochester Hills, MI | $14,806 | 34 |
| , MD | Family Medicine | Madison, WI | $10,707 | 16 |
| , MD | Endocrinology, Diabetes & Metabolism | Albuquerque, NM | $10,585 | 22 |
| , MD | Internal Medicine | Miami, FL | $10,474 | 20 |
| , M.D | Psychiatry | New York, NY | $9,800 | 5 |
| , M.D | Family Medicine | Chester Springs, PA | $9,110 | 24 |
| , MD | Child & Adolescent Psychiatry | Cleveland, OH | $8,895 | 18 |
| , M.D | Family Medicine | Roseville, CA | $8,878 | 26 |
| , M.D | Psychiatry | Richmond, VA | $8,687 | 14 |
| , MD | Psychiatry | New York, NY | $8,443 | 14 |
| , M.D | Psychiatry | Lutherville, MD | $8,310 | 18 |
| , MD | Psychiatry | Tampa, FL | $7,001 | 14 |
| , M.D | Family Medicine | Irvine, CA | $6,413 | 8 |
| , MD | Internal Medicine | Cromwell, CT | $5,621 | 8 |
| , MD | Psychiatry | North Andover, MA | $5,479 | 15 |
| , MD | Psychiatry | Mason, OH | $5,302 | 13 |
| , MD | Psychiatry | Lake Jackson, TX | $5,204 | 13 |
| , MD, MPH | Psychiatry | Pomona, NY | $5,055 | 8 |
| , MD | Psychiatry | Beaver, PA | $4,858 | 15 |
| , MD | Psychiatry | Cambridge, MA | $4,548 | 13 |
| , MD | Family Medicine | Atoka, TN | $4,375 | 11 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.4M
- Total Doctors 41
- Transactions 2,150
About DASOTRALINE
DASOTRALINE is a drug associated with $5.4M in payments to 41 healthcare providers, recorded across 2,150 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2017 to 2019. In 2019, $111,059 was paid across 197 transactions to 24 doctors.
The most common payment nature for DASOTRALINE is "Unspecified" ($5.2M, 95.7% of total).
DASOTRALINE is associated with 10 research studies, including "DASOTRALINE BINGE EATING DISORDER EXTENSION STUDY" ($1.8M).